Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Dehydroepiandrosterone, BAY86-5314 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Arm 1 | ACTIVE_COMPARATOR | - |
| Arm 2 | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Dehydroepiandrosterone, BAY86-5314 | DRUG | Treatment with daily oral intake of two capsules containing 50 mg DHEA each. Treatment duration will be 24 weeks |
| Placebo | DRUG | Treatment with daily oral intake of two capsules containing Placebo. Treatment duration will be 24 weeks |
Inclusion Criteria: * Treatment with a oral contraceptive (OC) for at least 3 months and willing to continue the OC * Loss of libido * Sexual relationship with a sexually competent partner Exclusion Criteria: * Female sexual dysfunction other than HSDD, arousal and orgasmic disorder, such as sexu...
Dehydroepiandrosterone (BAY86-5314) is an investigational small molecule being studied for the treatment of reduced libido in women. It is being developed as an oral therapy to be used as a concomitant treatment with oral contraceptives. The drug is currently in Phase 2 clinical development.
Dehydroepiandrosterone (BAY86-5314) is being developed by Bayer AG, a multinational pharmaceutical company. Bayer's stock is traded under the ticker symbol BAYRY on the OTC market. The company is conducting clinical trials to evaluate the drug's efficacy and safety for treating reduced libido.
Dehydroepiandrosterone (BAY86-5314) is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The drug is being studied for its potential to treat reduced libido in women who are also taking oral contraceptives.
Dehydroepiandrosterone (BAY86-5314) has one completed Phase 2 clinical trial registered as NCT00566384. This trial was a randomized, double-blind, placebo-controlled study that enrolled 100 female participants in Germany. The study evaluated the efficacy and safety of oral dehydroepiandrosterone as a concomitant therapy to oral contraceptives in women with reduced libido.
Dehydroepiandrosterone (BAY86-5314) is also known as DHEA, a common abbreviation for the compound. In clinical trials, it is referred to as dehydroepiandrosterone. The drug is being investigated by Bayer AG for its potential role in improving libido in women using oral contraceptives.